T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti–PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326–8. ©2017 AACR.
See related article by Tolcher et al., p. 5349
http://ift.tt/2fmhIwb
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου